DPP4 inhibitor
PreclinicalSmall molecule
AstraZenecaDPP4 inhibitor is one of 15 small molecule programs targeting Coronary Atherosclerosis. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Coronary Atherosclerosis
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Colcrys
Jazz PharmaceuticalsApproved
Actos
TakedaApproved
Mounjaro
Eli LillyApproved
Precose
BayerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Benicar
CCosette Pharmaceuticals, Inc.
Approved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Coronary Atherosclerosis1 trial
Type 2 Diabetes1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DPP4 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company